Quantcast
Last updated on April 24, 2014 at 10:33 EDT

Latest Arteriocyte Stories

2012-08-21 06:27:17

CLEVELAND, Aug. 21, 2012 /PRNewswire/ -- Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX(TM) platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells. The funding will enable development of the company's NANEX(TM) platform for use in stem cell transplants, a...

2012-04-06 06:22:03

CLEVELAND, April 6, 2012 /PRNewswire/ -- Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan MAR01(TM) technology in the treatment of Compartment Syndrome. The FDA Investigational Device Exemption (IDE 15013) allows Arteriocyte and its clinical partners to initiate evaluation of concentrated marrow injections (using...

2011-07-20 10:22:00

CLEVELAND, July 20, 2011 /PRNewswire/ -- Arteriocyte®, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies announced today that the Ohio Department of Development's Third Frontier Commission awarded a $1 million grant to the company for its "Development and Commercialization of Hematopoietic Stem Cell Expansion for Clinical Applications" as...

f309d24116c87b0a6dd2e3e3b3f9e1aa
2010-07-11 07:25:00

American scientists have developed "artificial blood" that could soon be used to treat soldiers who are wounded during battle. The artificial blood is created by taking cells from umbilical cords and using a machine to imitate the way bone marrow works to produce mass quantities of usable units of red blood cells. Producing the genetically-engineered blood is known as "Ëœblood pharming'. The program was launched in 2008 by the Pentagon's experimental sector, Darpa, to find a way...

2008-10-06 09:00:57

Arteriocyte, a clinical stage biotechnology company announced today that the company has been awarded $496,000 through the Global Cardiovascular Innovation Center (GCIC), to continue clinical research on its lead stem cell therapy (ACY001) for use in chronic coronary ischemia. This funding is in addition to the first year GCIC support received in 2007, to accelerate the company's cardiac stem cell therapy development. Under the GCIC project, Arteriocyte participates as one of a number of...

2008-09-24 12:00:37

Arteriocyte, a clinical stage biotechnology company, has received a fast track Phase I/II small business innovation research grant award from the National Heart, Lung, and Blood Institute, of the National Institutes of Health. The grant award is the first installment of the combined $2.5 million grant from the National Institutes of Health (NIH) to clinically evaluate the therapeutic feasibility of treating critical limb ischemia with the company's expanded human umbilical cord blood...

2008-09-22 09:00:59

Arteriocyte, a clinical stage biotechnology company announced today the receipt of a fast track Phase I/II Small Business Innovation Research Grant Award (R44HL092706-01) from National Heart, Lung, and Blood Institute (NHLBI), of the National Institutes of Health (NIH). The grant award, is the first installment of the combined $2.5 million grant from the NIH to clinically evaluate the therapeutic feasibility of treating Critical Limb Ischemia with the company's expanded human umbilical cord...